After finishing the year advising on the Disney acquisition of Fox (66B) Guggenheim has pulled off 2 more multi-billion dollar deals with the latest being Sanofi's acquisition of Bioverativ (11B). Many on this forum have said that Guggenheim is not an EB, is this changing and are exit opps improving as time goes on?
| +407 | Evercore Intern Seizure | 62 | 14h |
| +126 | UBS IB Americas has failed, now behind Santander and Stiffel | 34 | 3h |
| +79 | deleted deleted deleted deleted deleted | 44 | 7h |
| +60 | How do I understand vs. just memorizing? | 11 | 18h |
| +55 | Some banks are overrated as fuck | 16 | 1h |
| +49 | The good and bad with Wells Fargo | 15 | 6h |
| +48 | Associate & Above IB exits | 18 | 20h |
| +44 | Sent my Claude prompt to 200+ Teams chat. MD wants to see me Monday. | 25 | 1h |
| +36 | Incoming IB Analyst: Best Ways to Prepare? | 13 | 16h |
| +32 | Tech to IB Pivot | 20 | 1d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Guggenheim is without a doubt an EB and is moving up rapidly. Placement wise, I have heard mixed things, but in general have heard in the past they did not place as well as other EBs...but I assume that is changing as they continue to become more established.